Multispecialty hospital for active treatment Sveta Sofia EOOD

Running trials

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· Phase 3· Source

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· Phase 3· Source

• Recruiting

  A Two-part study to learn the amount of polymyxin E1 in the body over time formed after a single inhaled dose of colistimethate sodium (CMS) in healthy adults (Part 1) and after single inhaled and vein-infused doses of CMS in adults with non‑cystic fibrosis bronchiectasis (NCFB) (Part 2)

  2025-524324-22-00· Phase 1· Source

• Not yet recruiting

  A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy

  2026-527617-29-00· Phase 3· Source

• Not yet recruiting

  A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD

  2026-525216-34-00· Phase 2· Source

• Recruiting

  Phase 1 Single Dose Study of JADE201 in Participants with Rheumatoid Arthritis

  2025-524746-96-00· Phase 1· Source

• Active, not recruiting

  AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

  NCT07400107· Phase 3· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

  NCT07441642· Phase 2· Source

• Recruiting

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· Phase 3· Source

• Recruiting

  A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

  NCT07276724· Phase 3· Source

• Recruiting

  A study to find how well budoprutug (TNT119) works and how safe it is in participants with Systemic Lupus Erythematosus

  2024-520385-57-01· Phase 1· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Source

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· Phase 3· Source

• Active, not recruiting

  Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN)

  2024-515538-34-00· Phase 2/3· Source

• Recruiting

  A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

  NCT06613360· Phase 1· Source

• Recruiting

  A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  NCT06452277· Phase 3· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

  NCT05946941· Phase 3· Source

• Active, not recruiting

  HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

  NCT05636176· Phase 3· Source

• Active, not recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

  NCT05134441· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)3 recruiting
• Heart failure3 recruiting
• Lupus (SLE)2 recruiting
• Asthma1 recruiting
• Bladder cancer1 recruiting
• COPD1 recruiting
• Cystic fibrosis1 recruiting
• Lung cancer1 recruiting
• Macular degeneration1 recruiting
• Obesity1 recruiting
• Rheumatoid arthritis1 recruiting
• Sjögren's disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A trial to explore the efficacy and safety of IDOR-1117-2520 in adults with moderate to severe chronic plaque psoriasis, with or without psoriatic arthritis.

  2025-523051-64-00· Phase 2· Source

• Active, not recruiting

  A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

  NCT06806852· Phase 1· Source

• Completed

  A study to test Aumolertinib in European participants with genetically linked advanced Lung Cancer

  2024-519618-29-00· Phase 1· Source

• Active, not recruiting

  A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

  NCT06799520· Phase 1· Source

• Completed

  A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PRESent-2)

  2022-502880-39-00· Phase 2· Source

• Completed

  A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

  NCT05728489· Phase 1· Source

• Active, not recruiting

  Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

  NCT05588843· Phase 2· Source

• Completed

  A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

  NCT04320342· Phase 3· Source